The 2026 narrative review by Sever, Sikiric, and colleagues in Pharmaceuticals (MDPI, 19(10):1559) positions stable gastric pentadecapeptide BPC 157 as a prototype cytoprotective agent for liver injury. Across rodent models of paracetamol toxicity, alcohol damage, CCl4 exposure, and ischemia-reperfusion, BPC 157 attenuated hepatocyte injury, reduced oxidative stress markers, and preserved endothelial integrity — matching or outperforming standard hepatoprotective agents.
What Is the Scope and Framework of the 2026 Narrative Review?
The review, authored by Marko Sever, Predrag Sikiric, and collaborators and published in Pharmaceuticals (MDPI) in October 2026, uses Robert's cytoprotection as its organising framework. It compares BPC 157 against N-acetylcysteine, silymarin, and corticosteroids across animal models of acute and chronic liver injury, framing BPC 157 as a cytoprotective prototype rather than a conventional hepatotoxicity antidote.
Robert's cytoprotection, originally described for gastric mucosa, refers to the capacity of certain agents to protect cells from noxious injury without neutralising the injurious agent itself. The review extends this framework to hepatic tissue, arguing that BPC 157's pleiotropic actions on endothelial integrity, nitric oxide (NO) signalling, and oxidative stress pathways constitute a liver-specific cytoprotective profile. This conceptual reframing distinguishes BPC 157 from agents that act solely through antioxidant or anti-inflammatory mechanisms.
The authors draw on the Sikiric group's multi-decade preclinical programme at the University of Zagreb, supplementing it with independent replications and mechanistic studies published through 2026. The review does not present new primary data; it synthesises existing animal-model evidence and contextualises it against the mechanistic literature for comparator agents. This narrative structure means the conclusions are hypothesis-generating rather than confirmatory.
Which Animal Models Does the Review Prioritise, and What Do They Show?
The review prioritises four rodent injury models: paracetamol overdose, ethanol-induced hepatotoxicity, carbon tetrachloride fibrosis induction, and hepatic ischemia-reperfusion. Across all four, BPC 157 administration reduced serum ALT and AST elevations, attenuated histological hepatocyte necrosis, and preserved sinusoidal endothelial architecture relative to vehicle controls, regardless of whether the route was oral, subcutaneous, or intraperitoneal.
In the paracetamol model, rats receiving BPC 157 immediately after overdose showed markedly reduced hepatic lesion burden at 25-minute and 3-hour post-exposure timepoints, a finding from the Krakow group's earlier work that the review cites as foundational. The mechanism proposed involves maintenance of hepatic glutathione reserves and attenuation of reactive oxygen species (ROS) generation downstream of cytochrome P450 2E1 (CYP2E1) activation — the canonical APAP toxicity pathway.
In the CCl4 model, BPC 157 co-administration reduced ALT and AST elevations and preserved liver architecture with less centrilobular necrosis than controls. The ischemia-reperfusion data, corroborated by a 2025 PMC study (Demirtaş et al., PMC11857380), document significant mitigation of oxidative stress markers in hepatic tissue following lower-extremity I/R. This demonstrates that BPC 157's hepatoprotective effect extends to remote organ injury scenarios, not only direct hepatotoxin exposure.
What Molecular Mechanisms Does the Review Attribute to BPC 157's Hepatoprotective Effect?
The review identifies three converging mechanistic axes: selective eNOS upregulation while attenuating iNOS-driven cytotoxic NO; preservation of sinusoidal endothelial integrity via VEGFR2–Akt signalling; and suppression of oxidative stress through maintenance of superoxide dismutase, catalase activity, and glutathione homeostasis. These axes are presented as interdependent rather than parallel, forming a unified cytoprotective response.
The NO modulation argument is central to the review's theoretical contribution. Cytotoxic iNOS-derived NO is implicated in hepatocyte apoptosis and sinusoidal endothelial dysfunction across multiple liver injury models. BPC 157 is proposed to shift the NO balance toward the cytoprotective eNOS-derived pool, preserving microvascular flow and reducing peroxynitrite-mediated oxidative damage. This dual NO modulation distinguishes BPC 157 from non-selective NO inhibitors.
The endothelial integrity axis connects to the review's broader cytoprotection framework. Sinusoidal endothelial cells are among the first hepatic cell populations injured in ischemia-reperfusion and toxic hepatitis models. BPC 157's pro-angiogenic activity — mediated through the VEGFR2–Akt–eNOS cascade — is proposed to maintain sinusoidal perfusion and limit secondary hepatocyte injury following endothelial disruption.
How Does BPC 157 Compare to Standard Hepatoprotective Agents in the Review's Analysis?
The review compares BPC 157 against N-acetylcysteine, silymarin, and corticosteroids across the same animal-model frameworks. BPC 157 matched or exceeded NAC in paracetamol models at equivalent timepoints, outperformed silymarin on several oxidative-stress endpoints in the CCl4 model, and demonstrated a broader mechanistic profile than corticosteroids, which carry hepatotoxic risk in alcohol-associated hepatitis contexts.
N-acetylcysteine remains the clinical standard for paracetamol overdose, acting as a glutathione precursor to replenish hepatic GSH stores depleted by NAPQI (N-acetyl-p-benzoquinone imine). The review does not argue that BPC 157 should replace NAC in acute overdose management; rather, it proposes that BPC 157's endothelial and NO-modulatory mechanisms address injury dimensions that NAC does not. The authors frame this as complementary rather than competitive positioning.
Silymarin (milk thistle extract) is the most widely used hepatoprotective agent globally, with antioxidant, anti-inflammatory, and antifibrotic properties. The review notes that BPC 157 and silymarin share antioxidant endpoints but diverge in their effects on endothelial integrity and NO signalling — domains where silymarin has limited documented activity. The authors acknowledge that head-to-head preclinical comparisons are sparse and that dose-equivalence methodology varies across studies.
Corticosteroids present a more complex comparison. In severe alcohol-associated hepatitis, prednisolone remains a guideline-recommended option despite contested efficacy data. The review highlights that corticosteroids carry immunosuppressive and metabolic risks that BPC 157 does not share in preclinical models, though the absence of human safety data for BPC 157 makes any clinical risk comparison premature.
What Are the Evidence Limitations the Review Acknowledges?
The review explicitly acknowledges that all BPC 157 hepatoprotection data derive from animal models, with no completed human RCT for any liver indication. Heterogeneity in dosing regimens, administration routes, and injury-model protocols limits cross-study comparability. Regulatory status — BPC 157 has no approved human indication — is stated as a central constraint on clinical translation.
The narrative review format itself introduces selection and framing bias risks. The Sikiric group, which originated the BPC 157 research programme, is both the primary source of preclinical data and the authorship team of the review. The authors do not address this conflict of interest explicitly, which is a standard limitation of narrative versus systematic reviews. Independent replication of key hepatoprotective findings remains limited to a small number of groups.
Mechanistic extrapolation from rodent liver injury to human hepatic disease carries well-documented translational barriers. Rodent CYP enzyme profiles, hepatic regenerative capacity, and sinusoidal architecture differ meaningfully from human equivalents. The review does not quantify these translational gaps or apply established frameworks such as the ARRIVE guidelines for preclinical study quality assessment.
The review also does not address pharmacokinetic data in the context of liver disease. BPC 157's oral bioavailability, hepatic first-pass metabolism, and tissue distribution in the setting of compromised hepatic function remain uncharacterised. These gaps are material to any protocol design discussion and are not resolved by the preclinical efficacy data the review presents.
What Safety Considerations Apply to BPC 157 in the Context of Liver Disease?
No human safety data exist for BPC 157 in patients with liver disease. Its pro-angiogenic activity raises theoretical concern regarding hepatocellular carcinoma risk, since hepatic fibrosis and cirrhosis are established HCC precursors. The FDA's July 2026 PCAC review identified unresolved oncological signals as a primary concern, amplified in hepatic settings where angiogenic dysregulation drives tumour progression.
BPC 157 has no approved human indication as of 2026 and cannot be legally compounded under current US FDA regulations, pending completion of the PCAC rulemaking process. Practitioners should note that the preclinical hepatoprotective data summarised in the Sever and Sikiric review do not constitute a clinical evidence base sufficient to justify therapeutic use. The compound's interaction profile with hepatically-metabolised drugs — including NAC, corticosteroids, and antiviral agents used in chronic liver disease — has not been characterised in any human study.
The review itself does not present a dedicated safety analysis section; safety considerations are inferred from the mechanistic literature and from the broader BPC 157 regulatory record. Clinicians evaluating this literature should apply the same evidence-quality standards they would apply to any preclinical-only compound: the absence of observed adverse events in animal models does not establish human safety.
What Would Be Required to Translate These Findings to Clinical Practice?
Translation would require, at minimum: a Phase 1 pharmacokinetic study establishing hepatic metabolism and safety parameters; a Phase 2 dose-finding trial in a defined liver injury population with pre-specified biomarker endpoints; and independent replication of key preclinical findings by groups without ties to the originating research programme. The review's authors frame BPC 157 as warranting clinical investigation, not clinical deployment.
A well-designed Phase 2 trial in APAP overdose — where NAC provides an active comparator with established efficacy and the injury timeline is predictable — would represent the most tractable first human test of the hepatoprotective hypothesis. This design would allow direct comparison of BPC 157 against the current standard of care on shared biomarker endpoints (ALT, AST, INR, bilirubin) while controlling for injury severity.
Regulatory pathway clarity is also a prerequisite. The 2026 PCAC positive vote on BPC 157 for the 503A bulk list is non-binding and does not resolve the compound's IND status for liver indications. Any clinical trial would require a separate IND submission with a liver-specific safety and efficacy rationale, independent of the compounding pathway discussion. How Does the 2026 Demirtaş Critical Review Grade the Preclinical Evidence for BPC-157 in Rodent Ischemia–Reperfusion Injury — and What Should Performance Practitioners Actually Conclude? What Does 2026 Research Reveal About BPC-157 and Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis? What Does 2026 Research Reveal About BPC-157's Mechanisms in Rodent Ischemia–Reperfusion Injury — and What Are the Metabolic Performance Implications?